Evidence map›Paper›PMID 31285509›Full record

ArticleScientific reports2019

Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system.

Karthik Selvaraju, Arjan Mofers, Paola Pellegrini, Johannes Salomonsson, Alexandra Ahlner, Vivian Morad, Ellin-Kristina Hillert, Belen Espinosa, Elias S J Arnér, Lasse Jensen and 6 more

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Phytochemical study ofPharmaceutical biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Dienone Compounds: Targets and Pharmacological Responses.Journal of medicinal chemistry · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Karthik Selvaraju *Department of Medical and Health Sciences, Linköping University, SE-58183, Linköping, Sweden.
Arjan Mofers *Department of Medical and Health Sciences, Linköping University, SE-58183, Linköping, Sweden.
Paola PellegriniDepartment of Medical and Health Sciences, Linköping University, SE-58183, Linköping, Sweden.
Johannes SalomonssonDepartment of Physics, Chemistry and Biology, Linköping University, SE-58183, Linköping, Sweden.ORCID http://orcid.org/0000-0003-4810-3669
Alexandra AhlnerDepartment of Physics, Chemistry and Biology, Linköping University, SE-58183, Linköping, Sweden.
Vivian MoradDepartment of Physics, Chemistry and Biology, Linköping University, SE-58183, Linköping, Sweden.
Ellin-Kristina HillertDepartment of Oncology-Pathology, Karolinska Institutet, SE-17176, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-5619-6450
Belen EspinosaDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-17177, Stockholm, Sweden.
Elias S J ArnérDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-17177, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-4807-6114
Lasse JensenDepartment of Medical and Health Sciences, Linköping University, SE-58183, Linköping, Sweden.
Jonas MalmströmRecipharm AB, Box CB11303, SE-101 32, Stockholm, Sweden.
Maria V TurkinaDepartment of Clinical and Experimental Medicine SE-58185 Linköping University, Linköping, Sweden.
Padraig D'ArcyDepartment of Medical and Health Sciences, Linköping University, SE-58183, Linköping, Sweden.
Michael A WaltersDepartment of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, University of Minnesota, Minnesota, United States.ORCID http://orcid.org/0000-0001-5650-9277
Maria SunnerhagenDepartment of Physics, Chemistry and Biology, Linköping University, SE-58183, Linköping, Sweden.
Stig LinderDepartment of Medical and Health Sciences, Linköping University, SE-58183, Linköping, Sweden. Stig.Linder@liu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A large number of natural products have been advocated as anticancer agents. Many of these compounds contain functional groups characterized by chemical reactivity. It is not clear whether distinct mechanisms of action can be attributed to such compounds. We used a chemical library screening approach to demonstrate that a substantial fraction (~20%) of cytotoxic synthetic compounds containing Michael acceptor groups inhibit proteasome substrate processing and induce a cellular response characteristic of proteasome inhibition. Biochemical and structural analyses showed binding to and inhibition of proteasome-associated cysteine deubiquitinases, in particular ubiquitin specific peptidase 14 (USP14). The results suggested that compounds bind to a crevice close to the USP14 active site with modest affinity, followed by covalent binding. A subset of compounds was identified where cell death induction was closely associated with proteasome inhibition and that showed significant antineoplastic activity in a zebrafish embryo model. These findings suggest that proteasome inhibition is a relatively common mode of action by cytotoxic compounds containing Michael acceptor groups and help to explain previous reports on the antineoplastic effects of natural products containing such functional groups.

Indexed as

AnimalsAntineoplastic AgentsCatalytic DomainCell Line, TumorCell SurvivalDrug Screening Assays, AntitumorHCT116 CellsHeLa CellsHumansMCF-7 CellsProteasome Endopeptidase ComplexProteasome InhibitorsProtein BindingSmall Molecule LibrariesUbiquitin ThiolesteraseXenograft Model Antitumor AssaysAntineoplastic AgentsProteasome Endopeptidase ComplexProteasome InhibitorsSmall Molecule LibrariesUbiquitin ThiolesteraseUSP14 protein, human

Identifiers

PMID31285509
PMCPMC6614553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.